Upgrade to SI Premium - Free Trial

Dianthus Therapeutics (DNTH)

102.49 -2.28 (2.18%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

JPMorgan Starts Dianthus Therapeutics (DNTH) at Overweight September 11, 2026 3:26 AM - StreetInsider Citi initiates Dianthus Therapeutics coverage with Buy rating September 4, 2026 5:09 AM - StreetInsider This biotech stock still Wolfe's top pick as multiple catalysts loomh August 31, 2026 8:00 AM - StreetInsider Form 4 Dianthus Therapeutics, For: Aug 19 Filed by: Read Simon August 19, 2026 6:03 PM - SEC Filing Form 4 Dianthus Therapeutics, For: Aug 13 Filed by: Veness Adam M August 14, 2026 4:33 PM - SEC Filing Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: Sirenia Capital Management LP August 14, 2026 8:33 AM - SEC Filing Form SCHEDULE 13G Dianthus Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP August 13, 2026 4:06 PM - SEC Filing Form 4 Dianthus Therapeutics, For: Aug 10 Filed by: McGeorge Anne August 11, 2026 5:15 PM - SEC Filing Form 4 Dianthus Therapeutics, For: Aug 10 Filed by: Read Simon August 11, 2026 5:10 PM - SEC Filing Form 4 Dianthus Therapeutics, For: Aug 07 Filed by: Veness Adam M August 11, 2026 5:09 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: Veness Adam M August 10, 2026 4:51 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: Read Simon August 10, 2026 4:36 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: McGeorge Anne August 10, 2026 4:34 PM - SEC Filing Agomab proposes two new board members ahead of shareholder vote August 10, 2026 4:08 PM - StreetInsider Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors August 10, 2026 4:08 PM - StreetInsider Agomab proposes two new board members ahead of shareholder vote August 10, 2026 4:07 PM - StreetInsider Form 4 Dianthus Therapeutics, For: Aug 07 Filed by: Garcia Marino August 7, 2026 6:31 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: Garcia Marino August 7, 2026 4:38 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: Veness Adam M August 7, 2026 4:38 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: Garcia Marino August 7, 2026 4:20 PM - SEC Filing Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: T. Rowe Price Investment Management, Inc. August 7, 2026 2:28 PM - SEC Filing Form SCHEDULE 13G Dianthus Therapeutics, Filed by: T. Rowe Price Investment Management, Inc. August 7, 2026 2:23 PM - SEC Filing Dianthus Therapeutics (DNTH) PT Raised to $128 at Truist Securities August 6, 2026 7:21 AM - StreetInsider Dianthus Therapeutics (DNTH) PT Raised to $158 at H.C. Wainwright August 6, 2026 6:54 AM - StreetInsider Dianthus Therapeutics (DNTH) PT Raised to $131 at Raymond James August 5, 2026 6:39 AM - StreetInsider Dianthus Therapeutics (DNTH) Tops Q2 EPS by 77c August 4, 2026 5:17 PM - StreetInsider Form 10-Q Dianthus Therapeutics, For: Jun 30 August 4, 2026 4:08 PM - SEC Filing Form 8-K Dianthus Therapeutics, For: Aug 04 August 4, 2026 4:06 PM - SEC Filing Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results August 4, 2026 4:01 PM - Globe NewsWire Dianthus Therapeutics unveils new bifunctional fusion protein DNTH312 August 4, 2026 7:02 AM - StreetInsider Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases August 4, 2026 7:00 AM - Globe NewsWire Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) August 3, 2026 6:00 PM - Globe NewsWire Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: BlackRock, Inc. July 28, 2026 4:46 PM - SEC Filing Form 4 Dianthus Therapeutics, For: Jul 09 Filed by: Savitz Ryan July 13, 2026 5:00 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: Savitz Ryan July 9, 2026 4:27 PM - SEC Filing Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) July 2, 2026 4:01 PM - Globe NewsWire Dianthus starts Phase 3 trial of claseprubart in myasthenia gravis June 29, 2026 7:01 AM - StreetInsider Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis June 29, 2026 7:00 AM - Globe NewsWire Full Article List